OOIR: Observatory of International Research

Papers

(The TQCC of Current Opinion in Virology is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Editorial Board	181
Inhaled aerosol viral-vectored vaccines against tuberculosis	142
Mutational escape from cellular immunity in viral hepatitis: variations on a theme	116
Transmission patterns of hepatitis E virus	85
The enigmatic roles of Anelloviridae and Redondoviridae in humans	85
Interfering with SARS-CoV-2: are interferons friends or foes in COVID-19?	79
Adenoviral-vectored next-generation respiratory mucosal vaccines against COVID-19	73
Hepatitis-B virus: replication cycle, targets, and antiviral approaches	68
Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy	65
Future considerations for the mRNA-lipid nanoparticle vaccine platform	64
Colonization of peripheral ganglia by herpes simplex virus type 1 and 2	64
Editorial Board	63
Editorial overview: Viral pathogenesis	62
Virus–host protein interactions as footprints of human cytomegalovirus replication	60
Viral–host interactions during splicing and nuclear export of influenza virus mRNAs	55
Structural basis for neutralization of enterovirus	55
Human placental models for studying viral infections	54
Recent progress in development of monoclonal antibodies against human cytomegalovirus	49
Editorial overview: Mechanisms in the molecular interactions of plants with viruses and viroids	49
Editorial Board	47
The two faces of oligoadenylate synthetase-like: effective antiviral protein and negative regulator of innate immunity	45
Emerging technologies in the study of the virome	44
The journey of herpesvirus capsids and genomes to the host cell nucleus	43
New preventive strategies for respiratory syncytial virus infection in children	42
Hepatitis C virus envelope protein dynamics and the link to hypervariable region 1	40

Paramyxoviruses from bats: changes in receptor specificity and their role in host adaptation	39
Adenovirus – a blueprint for gene delivery	39
Time to ‘Mind the Gap’ in novel small molecule drug discovery for direct-acting antivirals for SARS-CoV-2	38
Shopping for phages? Unpacking design rules for therapeutic phage cocktails	38
Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection	36
Epigenetic control of the Epstein-Barr lifecycle	34
The enigma of picobirnaviruses: viruses of animals, fungi, or bacteria?	34
A complex immune communication between eicosanoids and pulmonary macrophages	34
A review of broadly protective monoclonal antibodies to treat Ebola virus disease	33
Engineering therapeutic phages for enhanced antibacterial efficacy	32
Platelets in the pathogenesis of flavivirus disease	31
Perspective on taxonomic classification of uncultivated viruses	30
Mitigation of evolved bacterial resistance to phage therapy	30
Editorial Board	29
Role of mucosal-associated invariant T cells in coronavirus disease 2019 vaccine immunogenicity	28
Tissue-resident memory T cells in protective immunity to influenza virus	28
Blood virome research in myalgic encephalomyelitis/chronic fatigue syndrome: challenges and opportunities	28
Asymmetry in icosahedral viruses	28
Hemagglutinin stability as a key determinant of influenza A virus transmission via air	27
Therapeutic vaccination strategies against EBOV by rVSV-EBOV-GP: the role of innate immunity	26
When good turns bad: how viruses exploit innate immunity factors	26
Does arbovirus emergence in humans require adaptation to domestic mosquitoes?	26
Retasking of canonical antiviral factors into proviral effectors	26
Mechanisms of HCV resistance to broadly neutralizing antibodies	25
Modeling zoonotic and vector-borne viruses	25
Antibody landscapes of SARS-CoV-2 can reveal novel vaccine and diagnostic targets	25
MicroRNA-mediated control of Epstein–Barr virus infection and potential diagnostic and therapeutic implications	24
MEK inhibitors as novel host-targeted antivirals with a dual-benefit mode of action against hyperinflammatory respiratory viral diseases	24
Nucleoside analogs for management of respiratory virus infections: mechanism of action and clinical efficacy	24
Oncogenic Animal Herpesviruses	24
Diagnosis and monitoring of virus-associated cancer using cell-free DNA	23
Immune responses to human respiratory coronaviruses infection in mouse models	23
Role of the viral polymerase during adaptation of influenza A viruses to new hosts	23
Deimmunization of flagellin adjuvant for clinical application	22
The impact of high-resolution structural data on stemming the COVID-19 pandemic	22
The virome of vector mosquitoes	22
Bat virome research: the past, the present and the future	21
Editorial overview	21
Advances in human monoclonal antibody therapy for HBV infection	21
Antigenic evolution of SARS coronavirus 2	21